bortezomibmultiple myelomamultidrug resistanceABC-transporterYB-1P-glycoproteinMRP1BCRPMVPбортезомибмножественная миеломамножественная лекарственная устойчивостьАВС-транспортерYB-1Р-гликопротеинMRP1BCRPMVPE.Yu. Rybalkina; N.N. KalitinЕ.Ю. Рыбалкина; Н.Н. Калитин1.Bessmaltsev S.S. Multiple myeloma(pathogenesis, clinic, diagnosis, differential diagnosis). Klinicheskaya onkogematologiya = Clinical Oncohematology 2013;6(3):237—57.(In Russ.).Бессмельцев С.С. Множественная миелома (патогенез, клиника, диагностика, дифференциальный диагноз). Клиническая онкогематология 2013;6(3):237—57.2.Moreau P., San Miguel J., Sonneveld P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl 4):iv52-61. DOI: 10.1093/annonc/mdx096. PMID: 28453614.3.Stavrovskaya A.A., Gens G.P. Some new aspects of the study of multidrug resistance of tumor cells. Espekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):5—11. (In Russ.).Ставровская А.А., Генс Г.П. Некоторые новые аспекты исследований множественной лекарственной устойчивости опухолевых клеток. Успехи молекулярной онкологии 2014;(1):5—11.4.Robey R., Pluchino K., Hall M. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18(7):452—64. DOI: 10.1038/s41568-018-0005-8. PMID: 29643473.5.Eliseeva I.A., Kim E.R., Guryanov S.G. et al. Boxing BINDING PROTEin 1 (YB-1) and its functions. Uspekhi biologicheskoy khimii = Advances in Biological Chemistry 2011;51:65-132. (In Russ.).Елисеева И.А., Ким Е.Р., Гурьянов С.Г. и др. Y-бокс-связывающий белок 1 (YB-1) и его функции. Успехи биологической химии 2011;51:65-132.6.Lasham A., Print C.G, Woolley A.G. et al. YB-1: oncoprotein, prognostic marker and therapeutic target. Biochem J 2013;449(1):11—23. DOI: 10.1042/bj20121323. PMID: 23216250.7.Stein U., Jurchott K., Walther W. et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J BiolChem 2001;276(30):28562—9. DOI: 10.1074/jbc.m100311200. PMID: 11369762.8.Stein U., Bergmann S., Scheffer G.L. et al. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 2005;24(22):3606—18. DOI: 10.1038/sj.onc.1208386. PMID:15750632.9.Wiberg K., Carlson K., Aleskog A. et al. In vitro activity of bortezomib in cultures of patient tumour cells-potential utility in haematological malignancies. Med Oncol 2009;26(2):193—201. DOI: 10.1007/s12032-008-9107-6. PMID: 19016012.10.Panishcheva L.A., Kakpakova E.S., Rybalkina E.Yu., Stavrovskaya A.A. Effect of the proteasome inhibitor bortezomib on gene expression of multidrug resistance and kinase activity. Biokhimiya = Biochemistry 2011;76(9):1238—47. (In Russ.).Панищева Л.А., Какпакова Е.С., Рыбалкина Е.Ю., Ставровская А.А. Влияние протеасомного ингибитора бортезомиба на экспрессию генов множественной лекарственной устойчивости и активность киназы. Биохимия 2011;76(9):1238—47.11.Scheffer G.L., Schroeijers A.B., Izquierdo M.A. et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12(6):550—6. DOI: 10.1097/00001622-200011000-00007. PMID: 11085454.12.Wang H., Wang X., Li Y. et. al. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi¬drug resistance through the NF-kappaB pathway. Pharmazie 2012;67(2):187—92. PMID: 22512091.13.Hu Y., Wang L., Wang L. et. al. Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function. Toxicol Appl Pharmacol 2015;283(1):1—8. DOI: 10.1016/j.taap.2014.12.015. PMID: 25576094.14.Chernykh Yu.B., Golenkov A.K., Shushanov S.S. The effect of gene expression of multidrug resistance on the clinical course of multiple myeloma. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine 2016;44(5):624—30. (In Russ.).Черных Ю.Б., Голенков А.К., Шушанов С.С. Влияние экспрессии генов множественной лекарственной устойчивости на клиническое течение множественной миеломы. Альманах клинической медицины 2016;44(5):624—30.15.Schwarzenbach H. Expression of MDR1/ P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Medical Oncology 2002;19(2):87—104. DOI: 10.1385/mo:19:2:87. PMID: 11085454.16.Izquierdo M.A., van der Zee A.G., Vermorken J.B. et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87(16):1230—7. DOI: 10.1093/jnci/87.16.1230. PMID: 7563169.17.Arts H.J., Katsaros D., de Vries E.G. et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999;5(10):2798—805. PMID: 10537344.18.Oda Y., Ohishi Y., Basaki Y. et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/ MVP and P-glycoprotein expression. Cancer Sci 2007;98(7):1020—6. DOI: 10.1111/j.1349-7006.2007.00492.x. PMID: 17459055.19.Balsas P., Galan-Malo P., Marzo I. et al. Bortezomib resistance in a myeloma cell line is associated to PSMp5 overexpression and polyploidy. Leuk Res 2012;36(2):212—8. DOI: 10.1016/j.leukres.2011.09.011. PMID: 21978467.20.Franke N.E., Kaspers G.L., Berg N. et al. Acquired resistance to bortezomib in human RPMI8226 multiple myeloma cells: molecular characterization, cross-resistance with other proteasome inhibitors but marked sensitization to glucocorticoids. Blood 2008;112:2640.21.Kim K.H., Cheong H.J., Lee M.Y. et al. Bortezomib is more effective to side population of RPMI8226 myeloma cells than classical anti-myeloma agents. Anticancer Res 2019;39(1):127–33. DOI: 10.21873/anticanres.13088. PMID: 30591449.22.Park J., Bae E.K. Lee C. et al. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep 2014;47(5):274–9. PMID: 24286313.Park J., Bae E.K. Lee C. et al. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep 2014;47(5):274–9. PMID: 24286313.